Rosenwald Amends Fortress Biotech Stake Filing

TL;DR

Rosenwald updated his Fortress Biotech filing - check for ownership changes.

AI Summary

Lindsay A. Rosenwald, M.D. has filed an amendment (Amendment No. 4) to Schedule 13D for Fortress Biotech, Inc. on September 25, 2024. This filing relates to the common stock of Fortress Biotech, Inc. and indicates a change in beneficial ownership as of September 23, 2024.

Why It Matters

This amendment signals a potential shift in the ownership structure or strategy of Fortress Biotech, Inc., which could influence its stock performance and future corporate actions.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D often indicate significant changes in a major shareholder's position, which can lead to increased volatility.

Key Players & Entities

• Lindsay A. Rosenwald, M.D. (person) — Filing person and beneficial owner
• Fortress Biotech, Inc. (company) — Subject company
• September 23, 2024 (date) — Date of event requiring filing
• September 25, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securiti
• $1.84 — shares of the Issuer's common stock at $1.84 per shares from the Issuer in a private

Filing Documents

• tm2424891d1_sc13da.htm (SC 13D/A) — 41KB
• 0001104659-24-102814.txt ( ) — 43KB

From the Filing

SC 13D/A 1 tm2424891d1_sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4)* Under the Securities Exchange Act of 1934 FORTRESS BIOTECH, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 34960Q 307 (CUSIP Number) Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (781) 652-4500 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 23, 2024 (Date of Event which Requires Filing of this If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise CUSIP No. 34960Q 307 Page 2 of 7 1. Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) Lindsay A. Rosenwald, M.D. 2. Check the Appropriate Box if a Member of a Group Not Applicable (a) ¨ (b) ¨ 3. SEC Use Only 4. Source of Funds (See Instructions) OO 5. Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) Not Applicable 6. Citizenship or Place of Organization United States 7. Sole Voting Power Number of 5,224,779 (1) Shares Beneficially 8. Shared Voting Power Owned By Each Reporting 0 Person with 9. Sole Dispositive Power 5,224,779 (1) 10. Shared Dispositive Power 0 11. Aggregate Amount Beneficially Owned by Each Reporting Person 5,224,779 (1) 12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (2) 13. Percent of Class Represented by Amount in Row (11) 18.4% 14. Type of Reporting Person IN CUSIP No. 34960Q 307 Page 3 of 7 (1) Includes 646,589 shares of unvested restricted Common Stock granted to the Reporting Person pursuant to the Fortress Biotech, Inc. Long Term Incentive Plan (and related Restricted Stock Award Agreements) and subject to repurchase until vested, and 1,567,515 shares underlying warrants that are currently exercisable. (2) The aggregate amount of shares of Common Stock owned by the Reporting Person reported in this Schedule 13D (Amendment No. 4) excludes (i) 96,919 shares of Common Stock held by LAR Family Trusts and trusts established for the benefit of the Reporting Person's family, over which the Reporting Person does not have voting for dispositive control and (ii) 763,359 shares of the Issuer's common stock underlying warrants held by the Reporting Person, which warrants will not become exercisable until March 23, 2025. CUSIP No. 34960Q 307 Page 4 of 7 Explanatory Note: This Amendment No. 4 (the " Amendment No. 4 ") amends and supplements the statement on Schedule 13D, Amendment No. 1, Amendment No. 2, and Amendment No. 3 to such Schedule 13D filed respectively on January 28, 2016, January 27, 2017, January 21, 2023, and January 3, 2024 (collectively, the " Schedule 13D ") with the U.S. Securities and Exchange Commission (the " SEC ") relating to the Common Stock of Fortress Biotech, Inc. (the " Issuer "), by Lindsay A. Rosenwald, M.D. (the " Reporting Person "). Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported on the Schedule 13D. Capitalized terms used but not defined herein shall have the same meanings as are ascribed to them in the Schedule 13D, as applicable. Item 1. Security and Issuer This amendment to a statement on Schedule 13D relates to the Common Stock, par value $0.001 per share (the " Common Stock ") of the Issuer. The Issuer's principal executive office is located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154. Item 2. Identity and Background (a) This Schedule 13D/A is being filed on behalf of the Reporting Person pursuant to Rule 13d-1 of Regulation D-G under the Act. (b) The address of the Reporting Person's principal business and principal office is 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154. (c) The principal business of the Reporting Person is that of President and Chief Executive Officer of the Issuer. The Reporting Person also serves as a member of the Issuer's Board of Directors. (d) – (e) During the last five years, the Reporting Person: (i) has not been convicted in any criminal proceeding (excluding traffic violations or simila

View Full Filing

View this SC 13D/A filing on SEC EDGAR